Search Results for 'dyadic'

The Digest’s 2022 Multi-Slide Guide to Dyadic

The Digest’s 2022 Multi-Slide Guide to Dyadic

August 11, 2022 |

One of the most interesting journeys in all of biotech — from jeans to jeans, and from cellulosic fuels over to pharma. Welcome to the story of Dyadic. Here are the markets, technologies, sources of revenues, trends, lines of business — launch-stage, growth-stage, maturity and end of life.

Read More

Protein Production Platform: The Digest’s 2021 Multi-Slide Guide to Dyadic

Protein Production Platform: The Digest’s 2021 Multi-Slide Guide to Dyadic

April 19, 2021 |

Now that all Americans 16 years and older are eligible for Covid-19 vaccines as of yesterday, the timing is perfect for this Dyadic presentation that dives into their proprietary & patented C1-cell chromosomal gene expression and recombinant protein production platform to which can produce large quantities of vaccines, antibodies, enzymes and other protein-based products.

Read More

Dyadic International vaccine candidate moving to human clinical trials

Dyadic International vaccine candidate moving to human clinical trials

March 22, 2021 |

In Florida, Dyadic International says that the company’s initial C1 produced SARS-CoV-2-S-RBD vaccine candidate, DYAI-100, is moving towards an anticipated safety and preliminary efficacy first in human Phase 1 clinical trial. Dyadic has entered into a master services agreement with CR2O, a full-service global contract research organization specializing in vaccinology, to manage preclinical and clinical […]

Read More

Dyadic takes next steps to list on NASDAQ

Dyadic takes next steps to list on NASDAQ

February 14, 2019 |

In Florida, Dyadic International, Inc. announced that the Securities and Exchange Commission (the “SEC”) has declared the Company’s Registration Statement on Form 10-12G (the “Form 10”) effective as of February 12, 2019.  As a result, the Company is now subject to the periodic and current reporting requirements of Section 13(a) of the Securities and Exchange […]

Read More

Dyadic tries again to launch IPO after government shutdown got in the way

Dyadic tries again to launch IPO after government shutdown got in the way

January 23, 2019 |

In Florida, Dyadic International announced that the Company has filed a replacement Registration Statement on Form 10-12G with the Securities and Exchange Commission. On November 5, 2018, the Company filed its initial Form 10-12G (File No. 000-55264), which was withdrawn on January 2, 2019 in order to prevent the Initial Form 10 from becoming effective […]

Read More

Dyadic authorizes new stock repurchase program

Dyadic authorizes new stock repurchase program

August 20, 2017 |

In Florida, Dyadic International, Inc. announced that its Board of Directors has authorized a new stock repurchase program, under which the Company may repurchase up to $5 million of its outstanding common stock. Under this new stock repurchase program, Dyadic may repurchase shares in accordance with all applicable securities laws and regulations, including Rule 10b-18 […]

Read More

DuPont’s $75M acquisition of Dyadic’s industrial biotechnology business closes

DuPont’s $75M acquisition of Dyadic’s industrial biotechnology business closes

January 3, 2016 |

In Florida, Dyadic International announced the closing of the previously announced sale of substantially all of the assets of its Industrial Technology business to DuPont’s Industrial Biosciences business for $75 million in cash.  As previously announced, following the closing, Dyadic intends to focus exclusively on its biopharmaceutical business. In connection with the closing of the […]

Read More

Dyadic reports 21% jump in Q3 product revenue and 69% gross profit gain, in Q3 results

Dyadic reports 21% jump in Q3 product revenue and 69% gross profit gain, in Q3 results

November 15, 2015 |

In Florida, Dyadic reported net Income for Q3 2015 of $1.3 million compared to a net loss of $1.2 million, or ($0.04) per basic and diluted share, for the same period a year ago. At September 30, 2015, cash and cash equivalents were approximately $6.3 million compared to $2.5 million at December 31, 2014. On […]

Read More

DuPont to give Dyadic $75 million Christmas present in thanks for C1 platform

DuPont to give Dyadic $75 million Christmas present in thanks for C1 platform

November 11, 2015 |

In Delaware, DuPont Industrial Biosciences has signed an agreement to purchase enzyme and technology assets from Dyadic International Inc., including Dyadic’s C1 platform, a fungal expression technology for producing enzymes. The transaction will further extend the world-leading biotechnology capabilities of DuPont’s Industrial Biosciences business. Under the terms of the agreement, DuPont will pay $75 million […]

Read More

Consolidation! Dyadic sells industrial technology biz to DuPont for $75M

Consolidation! Dyadic sells industrial technology biz to DuPont for $75M

November 11, 2015 |

As Dyadic cashes out of industrial biotech and retains a C1 license for pharma, DSM and Syngenta also announce a partnership. Companies are girding their loins for the long haul. The Digest takes a look, In Florida, DuPont Industrial Biosciences will acquire substantially all of the enzyme and technology assets Dyadic’s Industrial Technology business for $75 […]

Read More